Ocugen Reveals Data From Bharat Biotech Partnered Covaxin Booster Dose

Ocugen Inc OCGN announced that a booster shot of the COVID-19 vaccine candidate generated over a 10-fold increase in antibody levels across a range of coronavirus variants.

• Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Ocugen said that the studies on its effectiveness against the Omicron variant are ongoing. The results will be reported shortly.
• In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. 
• Related Link: Ocugen Partnered COVID-19 Vaccine Candidate Generates Immune Memory At Least 6 Months After Vaccination.
• Even after six months from the second dose, the antibody levels were detectable in more than 75% of all subjects.
• However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.
• The Company added that the data on the booster shot indicated no serious adverse events, including hospitalization or death. The study results are yet to undergo peer review.
• In November, Covaxin was granted the Emergency Use Listing by the World Health Organization.
• In December, Covaxin generated a broad antibody response in 2-18 years compared to adults.
• Price Action: OCGN shares are up 11.80% at $4.54 during the premarket session on the last check Monday.